Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
38.22
-0.01 (-0.03%)
At close: Mar 9, 2026, 4:00 PM EDT
38.20
-0.02 (-0.05%)
After-hours: Mar 9, 2026, 6:16 PM EDT
Crinetics Pharmaceuticals Revenue
In the year 2025, Crinetics Pharmaceuticals had annual revenue of $7.70M with 640.71% growth. Crinetics Pharmaceuticals had revenue of $6.16M in the quarter ending December 31, 2025.
Revenue (ttm)
$7.70M
Revenue Growth
+640.71%
P/S Ratio
519.99
Revenue / Employee
$12,956
Employees
594
Market Cap
4.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 6.66M | 640.71% |
| Dec 31, 2024 | 1.04M | -2.97M | -74.11% |
| Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
| Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
| Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Legend Biotech | 909.05M |
| Corcept Therapeutics | 761.41M |
| Amicus Therapeutics | 634.21M |
| TG Therapeutics | 616.29M |
| ADMA Biologics | 510.17M |
| Ligand Pharmaceuticals | 268.09M |
| Centessa Pharmaceuticals | 15.00M |
CRNX News
- 10 days ago - Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 6 weeks ago - Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 6 weeks ago - Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - GlobeNewsWire